As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular edema, prior to posting it online, and later, when I read the complete study as posted in Ophthalmology, the one thought that kept running through my mind was, why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?
And then I found out, when Andrew Pollack wrote the story behind the story later in the afternoon in the New (Read more...)